ELEDON PHARMACEUTICALS INC (ELDN) Stock Fundamental Analysis

NASDAQ:ELDN • US28617K1016

2.13 USD
+0.03 (+1.43%)
Last: Feb 19, 2026, 11:09 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ELDN scores 3 out of 10 in our fundamental rating. ELDN was compared to 521 industry peers in the Biotechnology industry. While ELDN has a great health rating, there are worries on its profitability. ELDN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ELDN had positive earnings in the past year.
  • ELDN had a negative operating cash flow in the past year.
  • In the past 5 years ELDN always reported negative net income.
  • ELDN had a negative operating cash flow in each of the past 5 years.
ELDN Yearly Net Income VS EBIT VS OCF VS FCFELDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • ELDN has a Return On Assets of -7.83%. This is amongst the best in the industry. ELDN outperforms 85.41% of its industry peers.
  • The Return On Equity of ELDN (-11.17%) is better than 87.33% of its industry peers.
Industry RankSector Rank
ROA -7.83%
ROE -11.17%
ROIC N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ELDN Yearly ROA, ROE, ROICELDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • ELDN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELDN Yearly Profit, Operating, Gross MarginsELDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ELDN has been increased compared to 1 year ago.
  • ELDN has more shares outstanding than it did 5 years ago.
  • ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELDN Yearly Shares OutstandingELDN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELDN Yearly Total Debt VS Total AssetsELDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ELDN has an Altman-Z score of -3.09. This is a bad value and indicates that ELDN is not financially healthy and even has some risk of bankruptcy.
  • ELDN's Altman-Z score of -3.09 is in line compared to the rest of the industry. ELDN outperforms 46.83% of its industry peers.
  • ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.09
ROIC/WACCN/A
WACCN/A
ELDN Yearly LT Debt VS Equity VS FCFELDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 6.74 indicates that ELDN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 6.74, ELDN is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
  • A Quick Ratio of 6.74 indicates that ELDN has no problem at all paying its short term obligations.
  • ELDN has a Quick ratio of 6.74. This is in the better half of the industry: ELDN outperforms 68.71% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
ELDN Yearly Current Assets VS Current LiabilitesELDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 112.44% over the past year.
EPS 1Y (TTM)112.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELDN will show a small growth in Earnings Per Share. The EPS will grow by 3.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.59%
EPS Next 2Y6.78%
EPS Next 3Y4.72%
EPS Next 5Y3.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELDN Yearly Revenue VS EstimatesELDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M
ELDN Yearly EPS VS EstimatesELDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 8.52, which indicates a very decent valuation of ELDN.
  • Based on the Price/Earnings ratio, ELDN is valued cheaply inside the industry as 98.46% of the companies are valued more expensively.
  • ELDN is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for ELDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 8.52
Fwd PE N/A
ELDN Price Earnings VS Forward Price EarningsELDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELDN Per share dataELDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • ELDN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y6.78%
EPS Next 3Y4.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ELDN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (2/19/2026, 11:09:00 AM)

2.13

+0.03 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-18
Inst Owners54.06%
Inst Owner Change22.04%
Ins Owners0.03%
Ins Owner Change9.66%
Market Cap168.78M
Revenue(TTM)N/A
Net Income(TTM)-10.17M
Analysts84.62
Price Target8.16 (283.1%)
Short Float %8.16%
Short Ratio8.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.12%
Min EPS beat(2)17.65%
Max EPS beat(2)44.59%
EPS beat(4)4
Avg EPS beat(4)110.73%
Min EPS beat(4)17.65%
Max EPS beat(4)306.56%
EPS beat(8)7
Avg EPS beat(8)29.64%
EPS beat(12)10
Avg EPS beat(12)21.49%
EPS beat(16)13
Avg EPS beat(16)17.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)-1.66%
EPS NQ rev (3m)16.77%
EPS NY rev (1m)-5.87%
EPS NY rev (3m)20.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8.52
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 2.88
EV/EBITDA N/A
EPS(TTM)0.25
EY11.74%
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS1.15
TBVpS0.74
PEG (NY)0.25
PEG (5Y)N/A
Graham Number2.54
Profitability
Industry RankSector Rank
ROA -7.83%
ROE -11.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -3.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.38%
EPS Next Y34.59%
EPS Next 2Y6.78%
EPS Next 3Y4.72%
EPS Next 5Y3.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.63%
OCF growth 3YN/A
OCF growth 5YN/A

ELEDON PHARMACEUTICALS INC / ELDN FAQ

What is the fundamental rating for ELDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELDN.


What is the valuation status for ELDN stock?

ChartMill assigns a valuation rating of 3 / 10 to ELEDON PHARMACEUTICALS INC (ELDN). This can be considered as Overvalued.


What is the profitability of ELDN stock?

ELEDON PHARMACEUTICALS INC (ELDN) has a profitability rating of 2 / 10.


Can you provide the financial health for ELDN stock?

The financial health rating of ELEDON PHARMACEUTICALS INC (ELDN) is 7 / 10.